ATE422162T1 - Verfahren zur vorhersage und verhinderung der resistenz gegen taxoid-verbindungen - Google Patents
Verfahren zur vorhersage und verhinderung der resistenz gegen taxoid-verbindungenInfo
- Publication number
- ATE422162T1 ATE422162T1 AT06838008T AT06838008T ATE422162T1 AT E422162 T1 ATE422162 T1 AT E422162T1 AT 06838008 T AT06838008 T AT 06838008T AT 06838008 T AT06838008 T AT 06838008T AT E422162 T1 ATE422162 T1 AT E422162T1
- Authority
- AT
- Austria
- Prior art keywords
- predicting
- prohibitin
- preventing resistance
- taxoid compounds
- taxoid
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
- C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
- C12Y205/01018—Glutathione transferase (2.5.1.18)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/44—Multiple drug resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7023—(Hyper)proliferation
- G01N2800/7028—Cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73765305P | 2005-11-17 | 2005-11-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE422162T1 true ATE422162T1 (de) | 2009-02-15 |
Family
ID=38067807
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06838008T ATE422162T1 (de) | 2005-11-17 | 2006-11-17 | Verfahren zur vorhersage und verhinderung der resistenz gegen taxoid-verbindungen |
Country Status (7)
Country | Link |
---|---|
US (3) | US8148086B2 (de) |
EP (1) | EP1948213B1 (de) |
AT (1) | ATE422162T1 (de) |
AU (1) | AU2006318722A1 (de) |
CA (1) | CA2630214A1 (de) |
DE (1) | DE602006005084D1 (de) |
WO (1) | WO2007061922A2 (de) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007061922A2 (en) | 2005-11-17 | 2007-05-31 | Children's Medical Center Corporation | Methods to predict and prevent resistance to taxoid compounds |
US20090258020A1 (en) * | 2008-01-07 | 2009-10-15 | Patrys Limited | Antibody designated barb3, barb3 related antibodies, and methods of making and using same |
WO2013043870A1 (en) * | 2011-09-23 | 2013-03-28 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to tissue targeting |
US10264976B2 (en) | 2014-12-26 | 2019-04-23 | The University Of Akron | Biocompatible flavonoid compounds for organelle and cell imaging |
US11045488B2 (en) | 2014-12-26 | 2021-06-29 | Nitto Denko Corporation | RNA interference agents for GST-π gene modulation |
US20180002702A1 (en) | 2014-12-26 | 2018-01-04 | Nitto Denko Corporation | Methods and compositions for treating malignant tumors associated with kras mutation |
US10792299B2 (en) | 2014-12-26 | 2020-10-06 | Nitto Denko Corporation | Methods and compositions for treating malignant tumors associated with kras mutation |
TWI715594B (zh) * | 2015-06-24 | 2021-01-11 | 日商日東電工股份有限公司 | 用於麩胱甘肽S轉移酶Pi(GST-π)基因調控之RNA干擾劑 |
CN108883171A (zh) * | 2015-11-13 | 2018-11-23 | 麻省理工学院 | 用于检测和调节癌细胞的方法和组合物 |
KR101854291B1 (ko) | 2016-02-16 | 2018-05-03 | 전남대학교산학협력단 | 프로히비틴 단백질에 대한 항체를 포함하는 혈액암 진단용 조성물 및 이를 포함하는 혈액암 진단용 키트 |
JP6899201B2 (ja) * | 2016-06-23 | 2021-07-07 | 日東電工株式会社 | 細胞死誘導剤、細胞増殖抑制剤及び細胞の増殖異常に起因する疾患の治療用医薬組成物 |
WO2018005991A1 (en) * | 2016-07-01 | 2018-01-04 | Luxtera, Inc. | Method and system for redundant light sources by utilizing two inputs of an integrated modulator |
US20200399681A1 (en) | 2018-02-23 | 2020-12-24 | Cornell University | Assay for detection of androgen receptor variants |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1791957B1 (de) * | 2004-09-23 | 2013-07-31 | AEterna Zentaris GmbH | Prohibitin als ziel für krebstherapie |
WO2007057746A2 (en) * | 2005-05-27 | 2007-05-24 | Aurelium Biopharma Inc. | Focused microarray and methods of diagnosing chemotherapeutic drug resistance in a cancer cell |
US20070122830A1 (en) * | 2005-11-10 | 2007-05-31 | Aurelium Biopharma Inc. | Prohibitin-directed diagnostics and therapeutics for cancer and chemotherapeutic drug resistance |
WO2007061922A2 (en) | 2005-11-17 | 2007-05-31 | Children's Medical Center Corporation | Methods to predict and prevent resistance to taxoid compounds |
-
2006
- 2006-11-17 WO PCT/US2006/044819 patent/WO2007061922A2/en active Application Filing
- 2006-11-17 US US12/085,125 patent/US8148086B2/en not_active Expired - Fee Related
- 2006-11-17 DE DE200660005084 patent/DE602006005084D1/de active Active
- 2006-11-17 CA CA 2630214 patent/CA2630214A1/en not_active Abandoned
- 2006-11-17 AU AU2006318722A patent/AU2006318722A1/en not_active Abandoned
- 2006-11-17 EP EP20060838008 patent/EP1948213B1/de active Active
- 2006-11-17 AT AT06838008T patent/ATE422162T1/de not_active IP Right Cessation
-
2012
- 2012-02-24 US US13/404,398 patent/US9151758B2/en not_active Expired - Fee Related
-
2015
- 2015-09-25 US US14/865,115 patent/US20160011211A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20090312405A1 (en) | 2009-12-17 |
US20160011211A1 (en) | 2016-01-14 |
DE602006005084D1 (de) | 2009-03-19 |
US20130028885A1 (en) | 2013-01-31 |
CA2630214A1 (en) | 2007-05-31 |
WO2007061922A3 (en) | 2007-10-18 |
WO2007061922A2 (en) | 2007-05-31 |
US9151758B2 (en) | 2015-10-06 |
AU2006318722A1 (en) | 2007-05-31 |
EP1948213A2 (de) | 2008-07-30 |
EP1948213B1 (de) | 2009-02-04 |
US8148086B2 (en) | 2012-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE422162T1 (de) | Verfahren zur vorhersage und verhinderung der resistenz gegen taxoid-verbindungen | |
CY1125027T1 (el) | Μονοκλωνικα αντισωματα κατα κλαουδινης-18 για τη θεραπεια του καρκινου | |
MX2009006627A (es) | Quinazolinas para la inhibicion de pdk1. | |
TNSN08375A1 (en) | Quinazolines for pdk1 inhibition | |
ATE547102T1 (de) | Carbolin-derivate zur behandlung von krebs | |
TR200906131T1 (tr) | Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e | |
CY1118169T1 (el) | Λεμφοκυτταρικο αντιγονο 75 (ly75) | |
CY1118143T1 (el) | Ετεροκυκλικες ενωσεις χρησιμες ως αναστολεις της pdk1 | |
RU2448096C3 (ru) | Диарилгидантоины | |
UA118645C2 (uk) | Спосіб комбінованої терапії раку наночастинками, що містять рапаміцин і альбумін | |
CY1108092T1 (el) | Ενωσεις και μεθοδοι για την αναστολη της μιτωτικης προοδου με την αναστολη της κινασης aurora | |
EA200900798A1 (ru) | Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы | |
EA200970738A1 (ru) | Ингибиторы активности akt | |
DK1951759T3 (da) | Anti-EGFR-antistoffer | |
BR112012008385A2 (pt) | inibidores de p13 cinase e uso dos mesmos. | |
EA200970403A1 (ru) | Бициклические триазолы в качестве модуляторов протеинкиназы | |
ATE483705T1 (de) | (lh-ind0l-7-yl)-(pyrimidin-2 -yl-amino) methanon derivate und verwandte verbindungen als igf-rl inhibitoren zur behandlung von krebs | |
EA200900571A1 (ru) | Композиции chk1 ингибиторов | |
EA201200323A1 (ru) | Соединения и композиции, как ингибиторы протеинкиназы | |
CL2009001274A1 (es) | Compuestos derivados de triazina sustituida, mediados por la inhibicion de la kinasa p13 y mtor; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento de diferentes tipos de cancer. | |
EA201170252A1 (ru) | Амидофеноксиндазолы в качестве ингибиторов c-мет | |
EA200971068A1 (ru) | Триазолиламинопиримидиновые соединения | |
BRPI0908635A8 (pt) | composto, composição farmacêutica e método de tratamento de câncer | |
DE502005007105D1 (de) | 4-amino-5-oxo-8-phenyl-5h-pyrido-ä2,3-dü-pyrimidin-derivate als inhibitoren der tyrosinkinasen und der raf-kinasen zur behandlung von tumoren | |
EA201170344A1 (ru) | Азаиндольные ингибиторы iap |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |